コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 nventional induction therapy (basiliximab or rabbit antithymocyte globulin).
2 bortezomib, methylprednisone, rituximab, and rabbit antithymocyte globulin.
3 and either 20 mg alemtuzumab or 6 mg per kg rabbit antithymocyte globulin.
4 lymphoid irradiation, cyclophosphamide, and rabbit-antithymocyte globulin.
5 after successful induction therapy using two rabbit antithymocyte globulins.
6 one were randomly assigned to receive either rabbit antithymocyte globulin (1.5 mg per kilogram of bo
8 zumab (one dose of 30 mg, in 70 patients) or rabbit antithymocyte globulin (a total of 6 mg per kilog
10 The addition of low, nondepleting doses of rabbit antithymocyte globulin (ATG) to human peripheral
11 transplant total lymphoid irradiation (TLI), rabbit antithymocyte globulin (ATG), and a single donor
12 poside, cytarabine, and melphalan as well as rabbit antithymocyte globulin before autologous HCT.
13 ey transplant recipients who were prescribed rabbit antithymocyte globulin, calcineurin inhibitor, my
14 steroid elimination at 1 week, and combined rabbit antithymocyte globulin/daclizumab induction, prev
17 We therefore tested T-cell depletion with rabbit antithymocyte globulin followed by sirolimus mono
18 phylactic CMVIG and induction with high-dose rabbit antithymocyte globulin (>10 mg/kg) were associate
20 ts required steroid therapy and one required rabbit antithymocyte globulin in addition to MMF and ste
21 on maintenance prednisone in the setting of rabbit antithymocyte globulin induction and tacrolimus a
22 der-drained PAK (n=47) transplants receiving rabbit antithymocyte globulin induction from June 1998 t
23 n early corticosteroid withdrawal regimen of rabbit antithymocyte globulin induction, tacrolimus, and
24 n early corticosteroid withdrawal regimen of rabbit antithymocyte globulin induction, tacrolimus, myc
26 The patient received methylprednisolone and rabbit antithymocyte globulin intravenously during scalp
28 is with CMVIG and appropriate induction with rabbit antithymocyte globulin may be important to reduce
29 recipient pretreatment with a single dose of rabbit antithymocyte globulin or alemtuzumab and posttra
30 late mofetil were required as well as either rabbit antithymocyte globulin or interleukin-2 receptor
31 ain immunosuppressive regimens that included rabbit antithymocyte globulin or tacrolimus/mycophenolat
32 cyclophosphamide, and 6.5 mg/kg intravenous rabbit antithymocyte globulin or to receive 1.0 g/m(2) i
33 ction categories: no-induction, alemtuzumab, rabbit antithymocyte globulin (r-ATG), and interleukin-2
34 ne were randomized for 3 different regimens: rabbit antithymocyte globulin (r-ATG)/EVR (N = 85); basi
35 to December 2008 who received induction with rabbit-antithymocyte globulin (r-ATG), alemtuzumab, or a
36 stics, we generated 1:1 pairs of alemtuzumab-rabbit antithymocyte globulin (rATG) (5330 pairs) and ba
37 Patients were treated with T cell-depleting rabbit antithymocyte globulin (rATG) (6 mg/kg, n = 17) o
38 when alemtuzumab induction was compared with rabbit antithymocyte globulin (rATG) (Thymoglobulin [Gen
39 ing strategies have not been established for rabbit antithymocyte globulin (rATG) after heart transpl
44 ne the safety and efficacy of induction with rabbit antithymocyte globulin (RATG) compared with inter
45 71 patients who received either steroids or rabbit antithymocyte globulin (RATG) for orthotopic live
46 adult recipients who received rituximab and rabbit antithymocyte globulin (rATG) in combination as i
47 teroid-free immunosuppression protocol using rabbit antithymocyte globulin (RATG) induction in orthot
49 discharge, we developed a protocol to extend rabbit antithymocyte globulin (rATG) induction therapy i
50 imus 1.5 mg versus MMF in patients receiving rabbit antithymocyte globulin (rATG) induction, mainly d
52 ients, who were randomized to receive either rabbit antithymocyte globulin (RATG) or steroids as indu
53 bsets were evaluated before and after adding rabbit antithymocyte globulin (rATG) to mixed lymphocyte
54 mparing single-dose (SD) versus divided-dose rabbit antithymocyte globulin (rATG), and a maintenance
56 ace, human leukocyte antigen (HLA) mismatch, rabbit antithymocyte globulin (RATG), interleukin-2 rece
57 ostatic proliferation by Ki-67(+) T cells in rabbit antithymocyte globulin (rATG)-treated patients th
59 tients exposed (4.23%) versus not exposed to rabbit antithymocyte globulin (rATG; 0.53%; P=0.019) or
60 n basiliximab (1998), daclizumab (1998), and rabbit antithymocyte globulin (rATG; 1999) replaced anti
61 tablished to assess clinical experience with rabbit antithymocyte globulin (rATG; Thymoglobulin) in l
63 e thousand consecutive LT patients receiving rabbit antithymocyte globulin+/-rituximab induction were
65 nosuppression was Tac-Pred based in nine and rabbit antithymocyte globulin-Tac based in six cases.
66 e-ITx was carried out under Tac-Pred in six, rabbit antithymocyte globulin-Tac in eight, and alemtuzu
68 d pretreatment with approximately 5 mg/kg of rabbit antithymocyte globulin (Thymoglobulin) in the hou
69 a randomized, international study comparing rabbit antithymocyte globulin (TMG) and basiliximab (BAS
70 tients with Aspergillus colonization, use of rabbit antithymocyte globulin was associated with 4-fold
71 ox-proportional hazard model, treatment with rabbit antithymocyte globulin was significantly associat
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。